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Objective: Hypertrophic obstructive cardiomyopathy has been proposed to be the
result of gene mutations of contractile proteins. However, we have previously shown
significant elevation of insulin-like growth factor-I (IGF-I) and transforming growth
factor-β1 (TGF-β1) at the messenger RNA, protein, and receptor levels in patients
with hypertrophic obstructive cardiomyopathy when compared with myocardium
from patients without this disorder. We hypothesized that this growth factor overex-
pression is a regional phenomenon. To test this hypothesis, we compared levels of
IGF-I and TGF-β1 in hypertrophic and nonhypertrophic myocardium within the
same group of patients with hypertrophic obstructive cardiomyopathy. 
Methods: Two biopsy specimens were obtained from each patient undergoing septal
myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy, from
hypertrophied septum and from nonhypertrophied myocardium (8 patients in total).
Clinical data were prospectively recorded. Messenger RNA levels for growth factor
were quantified by means of multiplex reverse transcriptase–polymerase chain reac-
tion, expressed as a densitometric ratio of growth factor/glyceraldehyde-3-phosphate
dehydrogenase. Protein levels were quantified by means of chemiluminescent slot
blot analysis. Growth factor proteins were used to generate a standard curve.
Results: IGF-I messenger RNA and protein levels in hypertrophic myocardium
were 2.6 and 2.9 times greater, respectively, than in nonhypertrophic myocardium
of the same patients (both P < .01). TGF-β1 messenger RNA and protein levels in
the hypertrophic myocardium were 2.5 and 2.8 times greater, respectively, than the
levels in the nonhypertrophied myocardium (both P < .01). There was a significant
correlation between the IGF-I protein ratio (hypertrophic/nonhypertrophic
myocardium) and the inducible left ventricular outflow tract gradients measured at
cardiac catheterization (r = 0.77, P = .025).
Conclusions: Myocardial overexpression of IGF-I and TGF-β1 is a regional phe-
nomenon in patients with hypertrophic obstructive cardiomyopathy and is likely
involved in the pathogenesis of the disorder.
Hypertrophic obstructive cardiomyopathy (HOCM) was originallydescribed in the 19th century and was characterized as left ven-tricular hypertrophy without any apparent cause. HOCM affectsapproximately 1 in 500 persons and is the most common cause ofsudden death in young athletes.1 The etiology of this disorder isnot known.
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HOCM has a strong familial component and therefore
several investigators have focused on a genetic etiology.
HOCM is characterized as a heterogeneous disease of the
sarcomere, with more than 100 mutations of myocardial
contractile protein-encoding areas identified.2 Genetic
mutations in patients with HOCM have been described in
those regions encoding for troponin T, troponin I, α-
tropomyosin, myosin-binding protein C, and the β-myosin
heavy and light chains. However, gene mutations cannot be
demonstrated for all patients with this disease, and the pre-
cise mechanism by which these mutations lead to hypertro-
phy is not known.3
HOCM is characterized by regional hypertrophy of
the interventricular septum, with variable involvement of the
remaining myocardium.4 Hemodynamic obstruction of
the left ventricular outflow tract is often observed. Missense
mutations do not fully explain the disparity between the
extent of hypertrophy in the septum versus that in the rest of
the myocardium in patients with HOCM. We have investi-
gated other potential mechanisms in the pathogenesis of this
disorder.5,6
The role of growth factors in the development of
myocardial hypertrophy has received increasing attention in
recent years.7-9 Insulin-like growth factor-I (IGF-I)10-12 and
transforming growth factor-β1 (TGF-β1),13,14 in particular,
have been closely linked to cardiomyocyte hypertrophy and
excessive production of extracellular matrix. We have pre-
viously demonstrated increased levels of IGF-I and TGF-β1
and normal levels of IGF-II and platelet-derived growth fac-
tor-B in hypertrophied septum of patients with HOCM
when compared with patients without HOCM.5,6 Protein,
messenger RNA, and receptor levels for IGF-I and TGF-β1
were increased in the hypertrophic HOCM myocardium
when compared with the hypertrophied septum of patients
with aortic stenosis, as well as with biopsy specimens from
the left ventricular free wall of patients with aortic stenosis,
stable angina, and dilated cardiomyopathy. Regional differ-
ences in patients without HOCM were not found.
Our findings of elevated growth factor levels in patients
with HOCM were surprising because the long-standing
hypertrophy of our patients with aortic stenosis was not
mediated by increased myocardial IGF-I and TGF-β1 lev-
els. Also, animal models of myocardial hypertrophy
induced by pressure overload resulted in a transient increase
in left ventricular IGF-I protein and mRNA levels,15,16 with
levels returning to baseline within 6 weeks despite ongoing
hypertension and increasing ventricular hypertrophy.
Because the nonhypertrophied HOCM myocardium was
exposed to the same intraventricular pressures as the hyper-
trophied HOCM myocardium, we hypothesized that excess
production of growth factors must be a localized phenome-
non. We also hypothesized that this regional overexpression
would lead to regional hypertrophy through a paracrine or
autocrine mechanism. If IGF-I and TGF-β1 protein and
mRNA levels in nonhypertrophied HOCM myocardium
were similar to the levels found in the myocardium of
patients with stable angina, aortic stenosis, and cardiomy-
opathy, the increased levels measured in the hypertrophied
region of the HOCM myocardium would be a localized
autonomous response and not a generalized systemic dis-
ease process. To test this hypothesis, we compared growth
factor protein levels, mRNA levels, and receptor levels in
hypertrophied septum to nonhypertrophied left ventricular
myocardium in 8 consecutive patients undergoing myec-
tomy for HOCM.
Methods
Myocardial Biopsies and Operative Methods
Biopsy samples were obtained from the resected hypertrophied
septum and from the nonhypertrophied left ventricular apex in 8
consecutive patients undergoing septal myectomy for severely
symptomatic HOCM. The hypertrophic region was localized by
intraoperative transesophageal echocardiography and visual
inspection. Each biopsy specimen was immediately frozen by, and
temporarily stored in, liquid nitrogen. All patients underwent a
septal myectomy and none required mitral valve replacement, as
previously described.17 All patients gave written informed consent
for biopsy tissue to be obtained through a protocol approved by the
Toronto General Hospital Human Experimentation Committee.
Evaluation of Growth Factor mRNA Levels
Myocardial biopsy specimens (7-20 mg) were homogenized in 1
mL of TRIzol (GIBCO BRL, Life Technologies, Inc, Burlington,
Canada) and then incubated on ice for 10 minutes. Chloroform
(300 µL) was added and the mixture was treated in a vortex for 15
seconds. The mixture was centrifuged at 14,000g for 10 minutes.
Then 2 µL of DNase (Amersham Pharmacia Biotech, Piscataway,
NJ) was added to the supernatant and incubated at 37°C for 15
minutes. Isopropanol (500 µL) was added and the solution was
incubated at –70°C for 60 minutes. Centrifugation (15 minutes at
14,000g) was repeated and the pellet was dissolved in diethyl
pyrocarbonate water. Total RNA concentration for each sample
was quantified spectrophotometrically.
Total RNA (10 µg/sample) was combined with 20 units of
Moloney murine leukemia virus reverse transcriptase (GIBCO
BRL, Life Technologies), 4 µL of 5 × reverse transcriptase reac-
tion buffer, 1 µL of 25 mmol/L deoxyribonucleoside triphos-
phatase, 2 µL of 0.1 mol/L dithiothreitol, 1 µL of 150 µmol/L
oligo deoxythymidine (20 oligomer), 1 µL of RNAse inhibitor,
and sterilized water to bring the total reaction volume to 20 µL.
After incubation at 37°C for 60 minutes, the reaction was stopped
and the RNA was denatured with the addition of 30 µL of 0.7
mol/L NaOH/45 mmol/L ethylenediaminetetraacetic acid. Single-
stranded complementary DNA was precipitated, resuspended in
water, and stored at –20°C.
Multiplex reverse transcriptase–polymerase chain reaction (RT-
PCR) was used for quantitative analysis of growth factor mRNAs,
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used
as the internal control. The specific human primer sequences and
Li et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 1   91
TX
ET
CS
P
A
CD
CH
D
CS
P
ED
IT
O
RI
A
L
their sizes are summarized in Table 1. The PCR (total volume 100
µL) contained 10 µL of 10× PCR buffer, 3 µL of 50 mmol/L
MgCl2, 1 µL each of 15 pmol GAPDH, IGF-I, or TGF-β1 forward
and reverse primer, 10 µL (100 ng) of single-stranded cDNA, 1 µL
of 25 mmol/L deoxyribonucleoside triphosphatase, 2.5 U of Taq
DNA polymerase, and sterile water. The samples were directly
transferred from ice to the thermal cycler (Perkin-Elmer Cetus;
Technical Lab Services, Toronto, Ontario, Canada), and 30 reaction
cycles were performed. The PCR products were run on a 1%
agarose gel, and the relative density of GAPDH and growth factor
bands were determined with a computerized densitometry system
(Bio-Rad Gel Doc 1000; Bio-Rad Laboratories, Inc, Mississauga,
Canada). After gel analysis, the PCR products of specific growth
factors were extracted from the gel.
Evaluation of Protein and Receptor Levels for Growth
Factor 
We5 have previously described our method of quantifying protein
levels for growth factor. Myocardial tissue was homogenized in 50
mmol/L Tris-HCl (pH 7.4), then centrifuged at 14,000g for 15
minutes at 4°C. Supernatant protein concentration was measured
by Bio-Rad protein assay. Myocardial protein, 10 µg, along with
serial concentrations of IGF-I and TGF-β1 standards (Sigma
Chemical Co, St Louis, Mo), were separately loaded onto a
polyvinylidene fluoxide microporous membrane with the use of
the Minifold II Slot Blotting System (Schleicher & Schuell,
Dassel, Germany). The membrane was dried and washed twice
with TBS-T buffer (50 mmol/L Tris-HCl buffer and 0.1% Tween-
20) for 10 minutes and treated with blocking buffer (Boehringer-
Mannheim, Mannheim, Germany) for 60 minutes. Monoclonal
antibodies against IGF-I and TGF-β1 and their receptors
(Cedarlane Laboratories, Ltd, Hornby, Ontario, Canada) (1: 3000,
diluted with 0.5× blocking buffer) were added and incubated
overnight at 4°C. The membrane was washed twice with TBS-T
and then incubated with goat anti-mouse horseradish peroxidase-
conjugated antibody (1:3000 dilution) (Bio-Rad) for 60 minutes at
room temperature. After being washed twice with TBS-T, IGF-I
and TGF-β1 protein levels were detected by chemiluminescence
(Boehringer-Mannheim). Densitometric analyses of the standards
and sample bands were performed with a Bio-Rad image analysis
system expressed as nanograms per gram of tissue.
Statistical Analysis
All values are expressed as mean ± SD, with the exception of cate-
gorical variables, which are expressed as percentages. Comparison
of protein, mRNA, and receptor levels of growth factor in hyper-
trophied and nonhypertrophied myocardium were performed with
paired t tests. Correlation between growth factor levels and septal
thickness and pressure gradient measurements were assessed with
Pearson product-moment coefficients.
Results
The preoperative clinical features of our patient population
are displayed in Table 2. All patients had severe symptoms
refractory to medical therapy. In addition, all patients had
marked septal hypertrophy and large left ventricular out-
flow tract gradients. Mitral regurgitation, associated with
severe systolic anterior motion, was mild in 2 patients,
moderate in 2 patients, and severe in 4 patients.
Perioperatively, all patients did well with the exception
of 1 patient who had a left hemispheric cerebral infarct 4
days after the operation. This patient continues to have a
mild hemiparesis. There were no other complications or
deaths.
TABLE 1. PCR primer sequences of growth factor genes
cDNA and
primer Sequence of primer Product size
GAPDH
Forward 5´-TGAAGGTCGGAGTCAACGGATTTGGT-3´ 983 bp
Reverse 5´-CATGTGGGCCATGAGGTCCACCAC-3´
IGF-I
Forward 5´-TCTTCAGTTCGTGTGTGGAGAC-3´ 180 bp
Reverse 5´-ACAGAGCGAGCTGACTTGGC-3´
TGF-β1
Forward 5´-ACCATTCATGGCATGAACCGG-3´ 411 bp
Reverse 5´-AGCGCACGATCATGTTGGACA-3´
PCR, Polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; bp, base pair; IGF-I, insulin-like growth factor-I; TGF-β1,
transforming growth factor-β1.
TABLE 2. Clinical data of patients with HOCM undergoing
septal myectomy (n = 8)
Characteristic 
Male sex, No. (%) 6 (75.0)
Age (y) 53.4 ± 12.5
Risk factors, No. (%)
Syncope 3 (37.5)
Atrial fibrillation 2 (25.0)
Ventricular tachycardia 1 (12.5)
Family history 4 (50.0)
Medications, No. (%)
β-Blockers 4 (50.0)
Disopyramide 4 (50.0)
Calcium channel blockers 0 (0)
Antiarrhythmic drugs 2 (25.0)
NYHA class 3.1 ± 0.4
CCS class 2.9 ± 0.6
LVOT obstruction (mm Hg) 
At rest 56.6 ± 28.3
Inducible 131.3 ± 51.9
Maximum septal thickness (mm) 21 ± 2.5
Mitral regurgitation (moderate or severe), No. (%) 6 (75.0)
Coronary artery disease, No. (%) 0 (0)
Plus-minus values are means ± SD. NYHA, New York Heart Association
heart failure classification; CCS, Canadian Cardiovascular Society angina
classification; LVOT, left ventricular outflow tract.
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Three months postoperatively, symptoms had markedly
improved. The mean New York Heart Association heart fail-
ure class decreased to 1.8 ± 0.5 from 3.1 ± 0.4 preoperatively
(P = .001), and the mean Canadian Cardiovascular Society
angina class decreased to 1.3 ± 0.5 from 2.9 ± 0.6 (P < .001).
Left ventricular outflow tract gradients also significantly
improved, with a mean gradient of 7.0 ± 2.8 mm Hg at rest
(vs 56.6 ± 28.3 mm Hg before the operation) and 14.4 ± 8.0
mm Hg after exercise (vs 131.3 ± 51.9 mm Hg before the
operation; both P < .001). None of the patients had mitral
regurgitation at the time of postoperative follow-up.
Figure 1 displays IGF-I protein levels from the hypertro-
phied septum and from the nonhypertrophied myocardium
for all 8 patients. IGF-I protein levels were significantly (P
< .001) higher in hypertrophied areas than in apical
myocardium (275.2 ± 82.2 vs 94 ± 30 ng/g of tissue). The
mean IGF-I protein ratio (hypertrophied/nonhypertrophied
myocardium) was 3.1 ± 0.9. TGF-β1 protein levels were
Figure 1. IGF-I protein levels in hypertrophied (HR) and nonhyper-
trophied (NHR) myocardium obtained from 8 patients with idio-
pathic HOCM were quantified with a slot blot analysis (inset).
IGF-I was used as the protein standard (STD). IGF-I levels were
significantly (P < .001) higher in hypertrophied regions. IGF-I pro-
tein levels in the HR and NHR myocardium of 3 randomly selected
patients are shown in the inset beside the IGF-I protein standards.
Figure 2. TGF-β1 protein levels in hypertrophied (HR) and nonhy-
pertrophied myocardium (NHR) obtained from 8 patients with idio-
pathic HOCM were quantified with a slot blot analysis (inset).
TGF-β1 was used as the protein standard (STD). TGF-β1 levels
were significantly (P < .001) higher in hypertrophied regions. TGF-
β1 protein levels in the HR and NHR myocardium of 3 randomly
selected patients are shown in the inset beside the TGF-β1 pro-
tein standards.
Figure 3. IGF-I mRNA levels, expressed as a ratio to glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) in hypertrophied (HR)
and nonhypertrophied myocardium (NHR) obtained from 8 patients
with idiopathic HOCM. IGF-I gene expression was significantly (P
< .01) higher in the hypertrophied regions.
Figure 4. TGF-β1 mRNA levels in hypertrophied (HR) and nonhy-
pertrophied myocardium (NHR) obtained from 8 patients with idio-
pathic HOCM. TGF-β1 gene expression was significantly (p < .001)
higher in the hypertrophied regions. G3PDH, Glyceraldehyde-3-
phosphate dehydrogenase.
Li et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 1   93
TX
ET
CS
P
A
CD
CH
D
CS
P
ED
IT
O
RI
A
L
also significantly higher (P < .001) in hypertrophied areas
than in nonhypertrophic regions (23.9 ± 7.5 vs 8.6 ± 2.3
ng/g of tissue, Figure 2). The mean TGF-β1 protein ratio
was 2.8 ± 0.7. Growth factor mRNA levels, expressed as a
ratio to GAPDH, are displayed in Figures 3 and 4. The IGF-
I mRNA levels in hypertrophic myocardium were signifi-
cantly higher than in nonhypertrophic regions (0.88 ± 0.43
vs 0.34 ± 0.14, respectively; P < .01). TGF-β1 mRNA lev-
els were also significantly (P < .001) elevated in the hyper-
trophied myocardium (0.69 ± 0.17 vs 0.28 ± 0.13 for
nonhypertrophic myocardium). The IGF-I and TGF-β1 pro-
tein and mRNA levels in the nonhypertrophic HOCM
myocardium were similar to the levels we previously found
in stable angina, aortic stenosis, and explanted ischemic
cardiomyopathic hearts.5,6
We were able to measure growth factor receptor levels in
5 of 8 patients. The amount of protein was not sufficient in
the remaining 3 patients. A statistically nonsignificant trend
toward higher growth factor receptor levels was observed in
hypertrophied areas for both IGF-I (mean ratio 1.9 ± 0.5; P
= .10) and TGF-β1 (mean ratio 1.8 ± 0.4; P = .08).
We performed correlation analyses between ratios of
growth factor protein levels (hypertrophied/nonhypertro-
phied myocardium) and clinical measurements of septal
hypertrophy. Pressure gradients (millimeters of mercury)
were measured at the time of cardiac catheterization at rest
and after induction with amyl nitrite. Maximum septal
thickness (millimeters) was recorded during intraoperative
transesophageal echocardiography. A good clinical correla-
tion existed between IGF-I protein ratios and inducible left
ventricular outflow tract gradients (r = 0.77, P = .025). The
correlation between TGF-β1 and clinical indices of hyper-
trophy was poor.
Discussion
HOCM may be inherited as a mendelian dominant charac-
teristic with variable penetrance and diverse phenotypic
expression.4 Regional hypertrophy with left ventricular out-
flow tract obstruction is a consistent characteristic.
Although many sarcomeric protein-encoding mutations
have been identified,3 these mutations do not account for
the regional disparity in myocardial hypertrophy that is
observed in patients with HOCM. We postulated that local-
ized overexpression of growth factors may be involved in
the pathogenesis of this regional hypertrophy.
Several investigators have studied the association
between growth factors and myocardial hypertrophy.9 IGF-I
has been demonstrated to stimulate in culture cardiomyocyte
hypertrophy in the absence of mechanical loading by
increasing gene expression, protein synthesis, and protein
accumulation.11,13 Duerr and associates demonstrated
hypertrophy of normal rat hearts in vivo after administration
of IGF-I,10 as well as hypertrophy and improved ventricular
function after myocardial infarction.18 Delaughter and col-
leagues19 used a transgenic mouse model to demonstrate
that persistent expression of IGF-I leads to physiologic and
then pathologic cardiac hypertrophy. Butt and Bishop20
reported that IGF-I acts synergistically with mechanical
loading to increase procollagen gene expression and metab-
olism in cardiac fibroblasts. Animal models of myocardial
hypertrophy induced by pressure overload result in a tran-
sient increase in left ventricular IGF-I protein and mRNA
levels.15,16 Although the increase in ventricular IGF-I levels
occurred with the onset of hypertension and hypertrophy, the
IGF-I levels returned to control levels within 6 weeks despite
the continued presence of hypertension and increasing ven-
tricular hypertrophy. The authors suggest that the transient
increase in myocardial IGF-I was necessary only to initiate
myocardial hypertrophy. Other investigators have demon-
strated that antihypertensive treatment of hypertensive rats
results in a significant reduction of previously elevated
myocardial IGF-I mRNA and protein levels.21,22
Clinical studies have revealed a strong correlation
between circulating IGF-I levels and left ventricular mass in
patients with systemic hypertension.23 Postmortem12 and
aorta–coronary sinus24 studies have demonstrated signifi-
cantly higher myocardial IGF-I protein levels in patients
with left ventricular hypertrophy than in controls.
Several investigators have also demonstrated a relation-
ship between TGF-β1 and myocardial hypertrophy,
although to a lesser degree than IGF-I. Villarreal and
Dillmann14 demonstrated that TGF-β1 gene expression is
transiently increased in hypertrophied myocardium. Butt
and Bishop20 reported that the addition of TGF-β1 to pres-
sure-loaded cardiac fibroblasts increases procollagen syn-
thesis. Decker and colleagues13 demonstrated that TGF-β1
enhances cardiomyocyte protein and myosin heavy chain
synthesis in the absence of mechanical loading, although to
a lesser extent than IGF-I.
We previously reported growth factor levels in patients
with HOCM compared with patients with pressure-induced
myocardial hypertrophy or no hypertrophy. We analyzed
IGF-I, IGF-II, TGF-β1, and platelet-derived growth factor-
B mRNA levels in resected hypertrophic septal specimens
of patients with HOCM and compared them with the
myocardium of patients with aortic stenosis, stable angina,
and ischemic cardiomyopathy.6 Hypertrophied myocardium
from patients with HOCM had significantly higher levels of
IGF-I and TGF-β1 gene expression than all other patient
groups. The mRNA levels for myocardial IGF-II and
platelet-derived growth factor-B did not differ among the
patient groups studied. Further studies revealed elevated
protein levels of IGF-I and TGF-β1, as well as increased
growth factor receptor binding site activity, in hypertrophic
specimens from patients with HOCM when compared with
other patient populations.5 In addition, we5 identified the
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cardiomyocyte as the major site of IGF-I receptors and the
fibroblast as the major site of TGF-β1 receptors. It is of par-
ticular interest that IGF-I and TGF-β1 levels from hypertro-
phied myocardium of patients with HOCM were
significantly higher (3- and 2-fold, respectively) than in
patients with load-induced hypertrophy, that is, aortic steno-
sis. This finding suggests that the localized increase in
growth factor levels in HOCM myocardium was not simply
a consequence of hypertension. In addition, IGF-I and TGF-
β1 protein, mRNA, and receptor levels in the left ventricu-
lar free wall of patients with stable angina and in the
endocardial septum of patients with aortic stenosis were
similar and did not differ from levels found in the nonhy-
pertrophic apical myocardium of patients with HOCM. It
should be stressed that in our previous studies, hypertrophic
and nonhypertrophic myocardial biopsy specimens were
compared between different patients with HOCM. In the
current study, apical and septal specimens were obtained
from the same patients.
The current study was performed to compare hypertro-
phied septum and nonhypertrophied apical myocardium in
patients undergoing subaortic myectomy for HOCM.
Comparisons were made within patients to determine
whether the elevated growth factor levels for IGF-I and TGF-
β1 were a regional phenomenon. We demonstrated signifi-
cantly increased IGF-I and TGF-β1 protein levels and gene
expression and a nonsignificant increase in receptor levels
only in the hypertrophied regions compared with the nonhy-
pertrophied myocardium. In addition, we found fair to good
correlation between IGF-I protein level and left ventricular
outflow tract gradients and septal thickness, important clini-
cal parameters in the evaluation of degree of hypertrophy.17
Fujiwara and associates25 and Tanaka, Fujiwara, and
Kawai26 have shown that the number and size of myocytes
are significantly increased in the hypertrophic region when
compared with the nonhypertrophic region of the left ven-
tricle in patients with HOCM. The increased number of
hypertrophied cardiomyocytes implies an embryonic origin
of this disease process, which in turn is consistent with
HOCM being a cause of stillbirths and the development of
HOCM during infancy. Since myocardial hypertrophy is
frequently seen in the late teens and early twenties of
patients with HOCM, we speculate that young patients with
HOCM will have higher hypertrophic myocardial levels of
IGF-I and TGF -β1 than adult patients. Consistent with this
hypothesis is the finding that cardiomyopathy develops
early as a result of cardiomyocyte hyperplasia in transgenic
mice that overexpress myocardial IGF-I.27 We believe the
regulation of IGF-I is abnormally increased because of the
loss of feedback regulation in the HOCM disease process.
The mechanism that causes localized increases in growth
factors in patients with HOCM is not known. The regional
elevations in IGF-I and TGF-β1 growth factor, mRNA, and
receptor levels cannot be explained by the intraventricular
hypertension alone, because nonhypertrophic myocardium
is exposed to the same pressures. Furthermore, many
patients with HOCM have asymmetric hypertrophy before
intraventricular pressures are elevated. As we previously
reported, the IGF-I and TGF-β1 growth factor, mRNA, and
receptor elevations in the globally hypertrophic myocardium
of patients with severe aortic stenosis were 2- to 3-fold less
than levels in hypertrophic myocardium of patients with
HOCM. We believe the growth factor increase is
autonomous and causes the hypertrophy through an
autocrine or paracrine phenomenon.5 Alternatively, the ele-
vation in growth factors may be a compensatory response to
contractile protein mutations or an unknown factor.
However, it is unclear why either of these possible mecha-
nisms would be localized to the septum.
Further studies are required of growth factor–associated
hypertrophy in HOCM. In particular, the mechanisms of
IGF-I and TGF-β1 regulation, the relationship between
growth factors and gene mutations, and the possibility of
prevention or reversal of growth factor–associated hypertro-
phy by means of antisense DNA therapy need to be ana-
lyzed. If therapeutic studies are successful in an animal
model, localized treatment may be possible in patients with
HOCM. By means of interventional technology similar to
that used for percutaneous alcohol septal ablation,28 adeno-
virus29 with growth factor antisense DNA with a tetracy-
cline-activated promotor could be delivered directly to the
hypertrophied myocardium in high-risk patients or in
patients considered for surgical correction.
In conclusion, we found localized elevations of protein
and mRNA levels for IGF-I and TGF-β1 in hypertrophied
septal myectomy specimens of patients with HOCM.
Elevated growth factor levels present a potentially novel
mechanism to explain the regionalized hypertrophy present
in patients with HOCM. Further studies need to be per-
formed to determine whether growth factor–targeted ther-
apy is a possibility for this important clinical disease.
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